Loading…
Apolipoprotein B‐associated cholesterol is a determinant of treatment outcome in patients with chronic hepatitis C virus infection receiving anti‐viral agents interferon‐alpha and ribavirin
Summary Background Hepatitis C virus (HCV) co‐opts very‐low‐density lipoprotein (VLDL) pathways for replication, secretion and entry into hepatocytes and associates with apolipoprotein B (apoB) in plasma. Each VLDL contains apoB‐100 and variable amounts of apolipoproteins E and C, cholesterol and t...
Saved in:
| Published in: | Alimentary pharmacology & therapeutics 2009-06, Vol.29 (12), p.1282-1290 |
|---|---|
| Main Authors: | , , , , , , |
| Format: | Article |
| Language: | English |
| Subjects: | |
| Citations: | Items that this one cites Items that cite this one |
| Online Access: | Get full text |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| cited_by | cdi_FETCH-LOGICAL-c4792-c7670fda1f3873c313820ad7cbed9670bfae288e0f8f8acfeb76f434b7bcfb9c3 |
|---|---|
| cites | cdi_FETCH-LOGICAL-c4792-c7670fda1f3873c313820ad7cbed9670bfae288e0f8f8acfeb76f434b7bcfb9c3 |
| container_end_page | 1290 |
| container_issue | 12 |
| container_start_page | 1282 |
| container_title | Alimentary pharmacology & therapeutics |
| container_volume | 29 |
| creator | SHERIDAN, D. A. PRICE, D. A. SCHMID, M. L. TOMS, G. L. DONALDSON, P. NEELY, D. BASSENDINE, M. F. |
| description | Summary
Background Hepatitis C virus (HCV) co‐opts very‐low‐density lipoprotein (VLDL) pathways for replication, secretion and entry into hepatocytes and associates with apolipoprotein B (apoB) in plasma. Each VLDL contains apoB‐100 and variable amounts of apolipoproteins E and C, cholesterol and triglycerides.
Aim To determine whether baseline lipid levels predicted treatment outcome.
Methods Retrospective analysis was performed of 250 chronic hepatitis C (CHC) patients who had received anti‐viral agents interferon‐alpha and ribavirin; 165 had a sustained virological response (SVR). Pre‐ and post‐treatment nonfasting lipid profiles were measured and non‐high‐density lipoprotein (non‐HDL) cholesterol (i.e. apoB‐associated) was calculated. Binary logistic regression analysis assessed factors independently associated with treatment outcome.
Results There was an independent association between higher apoB‐associated cholesterol (non‐HDL‐C) and increased odds of SVR (odds ratio 2.09, P = 0.042). In multivariate analysis, non‐HDL‐C was significantly lower in HCV genotype 3 (g3) than genotype 1 (P = 0.007); this was reversible upon eradication of HCVg3 (pre‐treatment non‐HDL‐C = 2.8 mmol/L, SVR = 3.6 mmol/L, P |
| doi_str_mv | 10.1111/j.1365-2036.2009.04012.x |
| format | article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_733101805</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>20660022</sourcerecordid><originalsourceid>FETCH-LOGICAL-c4792-c7670fda1f3873c313820ad7cbed9670bfae288e0f8f8acfeb76f434b7bcfb9c3</originalsourceid><addsrcrecordid>eNqNkctu1DAUhiMEotPCKyBvgFWCL5lcFiymI25SJViUteU4xx2PEjvYTi87HoF34k36JJx0RmWH8MY-9nd-__afZYTRguF4ty-YqNY5p6IqOKVtQUvKeHH7JFs9HjzNVpRXbc4bJk6y0xj3lNKqpvx5dsJa0fKmWq-y35vJD3byU_AJrCPn9z9_qRi9tipBT_TODxATBD8QG4kiPWAxWqdcIt6QFEClEZZiTtqPQFBjUsniViQ3Nu1QInhnNdnBsp9QZUuubZgjogZ0st6RABrstXVXBHUtWkBADURdPchYh3ca9OAWc8O0U4j1JNhOIWfdi-yZUUOEl8f5LPv-8cPl9nN-8fXTl-3mItdl3fJc1_h60ytmRFMLLZhoOFV9rTvoWzzqjALeNEBNYxqlDXR1ZUpRdnWnTddqcZa9PejiZ_2Y8VvkaKOGYVAO_BxlLQSjrKFrJN_8k-S0qijlHMHmAOrgYwxg5BTsqMKdZFQuUcu9XBKVS6JyiVo-RC1vsfXV8Y65G6H_23jMFoHXR0BFrQYTlNM2PnKcleuW8Rq59wfuxg5w998G5Obb5bISfwBDFs4t</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>20660022</pqid></control><display><type>article</type><title>Apolipoprotein B‐associated cholesterol is a determinant of treatment outcome in patients with chronic hepatitis C virus infection receiving anti‐viral agents interferon‐alpha and ribavirin</title><source>Wiley-Blackwell Read & Publish Collection</source><creator>SHERIDAN, D. A. ; PRICE, D. A. ; SCHMID, M. L. ; TOMS, G. L. ; DONALDSON, P. ; NEELY, D. ; BASSENDINE, M. F.</creator><creatorcontrib>SHERIDAN, D. A. ; PRICE, D. A. ; SCHMID, M. L. ; TOMS, G. L. ; DONALDSON, P. ; NEELY, D. ; BASSENDINE, M. F.</creatorcontrib><description>Summary
Background Hepatitis C virus (HCV) co‐opts very‐low‐density lipoprotein (VLDL) pathways for replication, secretion and entry into hepatocytes and associates with apolipoprotein B (apoB) in plasma. Each VLDL contains apoB‐100 and variable amounts of apolipoproteins E and C, cholesterol and triglycerides.
Aim To determine whether baseline lipid levels predicted treatment outcome.
Methods Retrospective analysis was performed of 250 chronic hepatitis C (CHC) patients who had received anti‐viral agents interferon‐alpha and ribavirin; 165 had a sustained virological response (SVR). Pre‐ and post‐treatment nonfasting lipid profiles were measured and non‐high‐density lipoprotein (non‐HDL) cholesterol (i.e. apoB‐associated) was calculated. Binary logistic regression analysis assessed factors independently associated with treatment outcome.
Results There was an independent association between higher apoB‐associated cholesterol (non‐HDL‐C) and increased odds of SVR (odds ratio 2.09, P = 0.042). In multivariate analysis, non‐HDL‐C was significantly lower in HCV genotype 3 (g3) than genotype 1 (P = 0.007); this was reversible upon eradication of HCVg3 (pre‐treatment non‐HDL‐C = 2.8 mmol/L, SVR = 3.6 mmol/L, P < 0.001).
Conclusions Higher apoB‐associated cholesterol is positively associated with treatment outcome in CHC patients receiving anti‐viral therapy, possibly due to competition between apoB‐containing lipoproteins and infectious low‐density HCV lipo‐viral particles for hepatocyte entry via shared lipoprotein receptors.</description><identifier>ISSN: 0269-2813</identifier><identifier>EISSN: 1365-2036</identifier><identifier>DOI: 10.1111/j.1365-2036.2009.04012.x</identifier><identifier>PMID: 19392865</identifier><language>eng</language><publisher>Oxford, UK: Blackwell Publishing Ltd</publisher><subject>Adult ; Antiviral Agents - therapeutic use ; Apolipoproteins B - genetics ; Apolipoproteins B - metabolism ; Biological and medical sciences ; Cholesterol - genetics ; Cholesterol - metabolism ; Digestive system ; Female ; Gastroenterology. Liver. Pancreas. Abdomen ; Hepatitis C virus ; Hepatitis C, Chronic - drug therapy ; Human viral diseases ; Humans ; Infectious diseases ; Interferon-alpha - therapeutic use ; Male ; Medical sciences ; Middle Aged ; Multivariate Analysis ; Pharmacology. Drug treatments ; Predictive Value of Tests ; Retrospective Studies ; Ribavirin - therapeutic use ; Treatment Outcome ; Viral diseases ; Viral hepatitis</subject><ispartof>Alimentary pharmacology & therapeutics, 2009-06, Vol.29 (12), p.1282-1290</ispartof><rights>2009 Blackwell Publishing Ltd</rights><rights>2009 INIST-CNRS</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c4792-c7670fda1f3873c313820ad7cbed9670bfae288e0f8f8acfeb76f434b7bcfb9c3</citedby><cites>FETCH-LOGICAL-c4792-c7670fda1f3873c313820ad7cbed9670bfae288e0f8f8acfeb76f434b7bcfb9c3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,776,780,27901,27902</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=21459127$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/19392865$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>SHERIDAN, D. A.</creatorcontrib><creatorcontrib>PRICE, D. A.</creatorcontrib><creatorcontrib>SCHMID, M. L.</creatorcontrib><creatorcontrib>TOMS, G. L.</creatorcontrib><creatorcontrib>DONALDSON, P.</creatorcontrib><creatorcontrib>NEELY, D.</creatorcontrib><creatorcontrib>BASSENDINE, M. F.</creatorcontrib><title>Apolipoprotein B‐associated cholesterol is a determinant of treatment outcome in patients with chronic hepatitis C virus infection receiving anti‐viral agents interferon‐alpha and ribavirin</title><title>Alimentary pharmacology & therapeutics</title><addtitle>Aliment Pharmacol Ther</addtitle><description>Summary
Background Hepatitis C virus (HCV) co‐opts very‐low‐density lipoprotein (VLDL) pathways for replication, secretion and entry into hepatocytes and associates with apolipoprotein B (apoB) in plasma. Each VLDL contains apoB‐100 and variable amounts of apolipoproteins E and C, cholesterol and triglycerides.
Aim To determine whether baseline lipid levels predicted treatment outcome.
Methods Retrospective analysis was performed of 250 chronic hepatitis C (CHC) patients who had received anti‐viral agents interferon‐alpha and ribavirin; 165 had a sustained virological response (SVR). Pre‐ and post‐treatment nonfasting lipid profiles were measured and non‐high‐density lipoprotein (non‐HDL) cholesterol (i.e. apoB‐associated) was calculated. Binary logistic regression analysis assessed factors independently associated with treatment outcome.
Results There was an independent association between higher apoB‐associated cholesterol (non‐HDL‐C) and increased odds of SVR (odds ratio 2.09, P = 0.042). In multivariate analysis, non‐HDL‐C was significantly lower in HCV genotype 3 (g3) than genotype 1 (P = 0.007); this was reversible upon eradication of HCVg3 (pre‐treatment non‐HDL‐C = 2.8 mmol/L, SVR = 3.6 mmol/L, P < 0.001).
Conclusions Higher apoB‐associated cholesterol is positively associated with treatment outcome in CHC patients receiving anti‐viral therapy, possibly due to competition between apoB‐containing lipoproteins and infectious low‐density HCV lipo‐viral particles for hepatocyte entry via shared lipoprotein receptors.</description><subject>Adult</subject><subject>Antiviral Agents - therapeutic use</subject><subject>Apolipoproteins B - genetics</subject><subject>Apolipoproteins B - metabolism</subject><subject>Biological and medical sciences</subject><subject>Cholesterol - genetics</subject><subject>Cholesterol - metabolism</subject><subject>Digestive system</subject><subject>Female</subject><subject>Gastroenterology. Liver. Pancreas. Abdomen</subject><subject>Hepatitis C virus</subject><subject>Hepatitis C, Chronic - drug therapy</subject><subject>Human viral diseases</subject><subject>Humans</subject><subject>Infectious diseases</subject><subject>Interferon-alpha - therapeutic use</subject><subject>Male</subject><subject>Medical sciences</subject><subject>Middle Aged</subject><subject>Multivariate Analysis</subject><subject>Pharmacology. Drug treatments</subject><subject>Predictive Value of Tests</subject><subject>Retrospective Studies</subject><subject>Ribavirin - therapeutic use</subject><subject>Treatment Outcome</subject><subject>Viral diseases</subject><subject>Viral hepatitis</subject><issn>0269-2813</issn><issn>1365-2036</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2009</creationdate><recordtype>article</recordtype><recordid>eNqNkctu1DAUhiMEotPCKyBvgFWCL5lcFiymI25SJViUteU4xx2PEjvYTi87HoF34k36JJx0RmWH8MY-9nd-__afZYTRguF4ty-YqNY5p6IqOKVtQUvKeHH7JFs9HjzNVpRXbc4bJk6y0xj3lNKqpvx5dsJa0fKmWq-y35vJD3byU_AJrCPn9z9_qRi9tipBT_TODxATBD8QG4kiPWAxWqdcIt6QFEClEZZiTtqPQFBjUsniViQ3Nu1QInhnNdnBsp9QZUuubZgjogZ0st6RABrstXVXBHUtWkBADURdPchYh3ca9OAWc8O0U4j1JNhOIWfdi-yZUUOEl8f5LPv-8cPl9nN-8fXTl-3mItdl3fJc1_h60ytmRFMLLZhoOFV9rTvoWzzqjALeNEBNYxqlDXR1ZUpRdnWnTddqcZa9PejiZ_2Y8VvkaKOGYVAO_BxlLQSjrKFrJN_8k-S0qijlHMHmAOrgYwxg5BTsqMKdZFQuUcu9XBKVS6JyiVo-RC1vsfXV8Y65G6H_23jMFoHXR0BFrQYTlNM2PnKcleuW8Rq59wfuxg5w998G5Obb5bISfwBDFs4t</recordid><startdate>200906</startdate><enddate>200906</enddate><creator>SHERIDAN, D. A.</creator><creator>PRICE, D. A.</creator><creator>SCHMID, M. L.</creator><creator>TOMS, G. L.</creator><creator>DONALDSON, P.</creator><creator>NEELY, D.</creator><creator>BASSENDINE, M. F.</creator><general>Blackwell Publishing Ltd</general><general>Blackwell</general><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7T5</scope><scope>7U9</scope><scope>H94</scope><scope>7X8</scope></search><sort><creationdate>200906</creationdate><title>Apolipoprotein B‐associated cholesterol is a determinant of treatment outcome in patients with chronic hepatitis C virus infection receiving anti‐viral agents interferon‐alpha and ribavirin</title><author>SHERIDAN, D. A. ; PRICE, D. A. ; SCHMID, M. L. ; TOMS, G. L. ; DONALDSON, P. ; NEELY, D. ; BASSENDINE, M. F.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c4792-c7670fda1f3873c313820ad7cbed9670bfae288e0f8f8acfeb76f434b7bcfb9c3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2009</creationdate><topic>Adult</topic><topic>Antiviral Agents - therapeutic use</topic><topic>Apolipoproteins B - genetics</topic><topic>Apolipoproteins B - metabolism</topic><topic>Biological and medical sciences</topic><topic>Cholesterol - genetics</topic><topic>Cholesterol - metabolism</topic><topic>Digestive system</topic><topic>Female</topic><topic>Gastroenterology. Liver. Pancreas. Abdomen</topic><topic>Hepatitis C virus</topic><topic>Hepatitis C, Chronic - drug therapy</topic><topic>Human viral diseases</topic><topic>Humans</topic><topic>Infectious diseases</topic><topic>Interferon-alpha - therapeutic use</topic><topic>Male</topic><topic>Medical sciences</topic><topic>Middle Aged</topic><topic>Multivariate Analysis</topic><topic>Pharmacology. Drug treatments</topic><topic>Predictive Value of Tests</topic><topic>Retrospective Studies</topic><topic>Ribavirin - therapeutic use</topic><topic>Treatment Outcome</topic><topic>Viral diseases</topic><topic>Viral hepatitis</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>SHERIDAN, D. A.</creatorcontrib><creatorcontrib>PRICE, D. A.</creatorcontrib><creatorcontrib>SCHMID, M. L.</creatorcontrib><creatorcontrib>TOMS, G. L.</creatorcontrib><creatorcontrib>DONALDSON, P.</creatorcontrib><creatorcontrib>NEELY, D.</creatorcontrib><creatorcontrib>BASSENDINE, M. F.</creatorcontrib><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>Immunology Abstracts</collection><collection>Virology and AIDS Abstracts</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>MEDLINE - Academic</collection><jtitle>Alimentary pharmacology & therapeutics</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>SHERIDAN, D. A.</au><au>PRICE, D. A.</au><au>SCHMID, M. L.</au><au>TOMS, G. L.</au><au>DONALDSON, P.</au><au>NEELY, D.</au><au>BASSENDINE, M. F.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Apolipoprotein B‐associated cholesterol is a determinant of treatment outcome in patients with chronic hepatitis C virus infection receiving anti‐viral agents interferon‐alpha and ribavirin</atitle><jtitle>Alimentary pharmacology & therapeutics</jtitle><addtitle>Aliment Pharmacol Ther</addtitle><date>2009-06</date><risdate>2009</risdate><volume>29</volume><issue>12</issue><spage>1282</spage><epage>1290</epage><pages>1282-1290</pages><issn>0269-2813</issn><eissn>1365-2036</eissn><abstract>Summary
Background Hepatitis C virus (HCV) co‐opts very‐low‐density lipoprotein (VLDL) pathways for replication, secretion and entry into hepatocytes and associates with apolipoprotein B (apoB) in plasma. Each VLDL contains apoB‐100 and variable amounts of apolipoproteins E and C, cholesterol and triglycerides.
Aim To determine whether baseline lipid levels predicted treatment outcome.
Methods Retrospective analysis was performed of 250 chronic hepatitis C (CHC) patients who had received anti‐viral agents interferon‐alpha and ribavirin; 165 had a sustained virological response (SVR). Pre‐ and post‐treatment nonfasting lipid profiles were measured and non‐high‐density lipoprotein (non‐HDL) cholesterol (i.e. apoB‐associated) was calculated. Binary logistic regression analysis assessed factors independently associated with treatment outcome.
Results There was an independent association between higher apoB‐associated cholesterol (non‐HDL‐C) and increased odds of SVR (odds ratio 2.09, P = 0.042). In multivariate analysis, non‐HDL‐C was significantly lower in HCV genotype 3 (g3) than genotype 1 (P = 0.007); this was reversible upon eradication of HCVg3 (pre‐treatment non‐HDL‐C = 2.8 mmol/L, SVR = 3.6 mmol/L, P < 0.001).
Conclusions Higher apoB‐associated cholesterol is positively associated with treatment outcome in CHC patients receiving anti‐viral therapy, possibly due to competition between apoB‐containing lipoproteins and infectious low‐density HCV lipo‐viral particles for hepatocyte entry via shared lipoprotein receptors.</abstract><cop>Oxford, UK</cop><pub>Blackwell Publishing Ltd</pub><pmid>19392865</pmid><doi>10.1111/j.1365-2036.2009.04012.x</doi><tpages>9</tpages><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0269-2813 |
| ispartof | Alimentary pharmacology & therapeutics, 2009-06, Vol.29 (12), p.1282-1290 |
| issn | 0269-2813 1365-2036 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_733101805 |
| source | Wiley-Blackwell Read & Publish Collection |
| subjects | Adult Antiviral Agents - therapeutic use Apolipoproteins B - genetics Apolipoproteins B - metabolism Biological and medical sciences Cholesterol - genetics Cholesterol - metabolism Digestive system Female Gastroenterology. Liver. Pancreas. Abdomen Hepatitis C virus Hepatitis C, Chronic - drug therapy Human viral diseases Humans Infectious diseases Interferon-alpha - therapeutic use Male Medical sciences Middle Aged Multivariate Analysis Pharmacology. Drug treatments Predictive Value of Tests Retrospective Studies Ribavirin - therapeutic use Treatment Outcome Viral diseases Viral hepatitis |
| title | Apolipoprotein B‐associated cholesterol is a determinant of treatment outcome in patients with chronic hepatitis C virus infection receiving anti‐viral agents interferon‐alpha and ribavirin |
| url | http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-03T03%3A01%3A00IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Apolipoprotein%20B%E2%80%90associated%20cholesterol%20is%20a%20determinant%20of%20treatment%20outcome%20in%20patients%20with%20chronic%20hepatitis%20C%20virus%20infection%20receiving%20anti%E2%80%90viral%20agents%20interferon%E2%80%90alpha%20and%20ribavirin&rft.jtitle=Alimentary%20pharmacology%20&%20therapeutics&rft.au=SHERIDAN,%20D.%20A.&rft.date=2009-06&rft.volume=29&rft.issue=12&rft.spage=1282&rft.epage=1290&rft.pages=1282-1290&rft.issn=0269-2813&rft.eissn=1365-2036&rft_id=info:doi/10.1111/j.1365-2036.2009.04012.x&rft_dat=%3Cproquest_cross%3E20660022%3C/proquest_cross%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c4792-c7670fda1f3873c313820ad7cbed9670bfae288e0f8f8acfeb76f434b7bcfb9c3%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=20660022&rft_id=info:pmid/19392865&rfr_iscdi=true |